Janssen’s Stelara has gained FDA approval for use in patients with Crohn’s disease who have failed treatment or were intolerant to a TNF blocker drug. The monoclonal antibody drug targets ...

Stelara was first approved for psoriasis 10 years ago, and follow-up indications in psoriatic arthritis and Crohn’s disease have kept the drug growing at a healthy pace to reach more than $5 ...

linking the pathogenesis of Crohn’s disease with this inflammation pathway. The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

The global market for ustekinumab, Stelara's active ingredient ... options to patients diagnosed with ulcerative colitis, Crohn's disease, psoriasis, and psoriatic arthritis,” said Celltrion ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Vigorous protection of Stelara’s position in the immunology ... colitis and an expected approval of the therapy for Crohn’s disease. Duato also mentioned that the company views the future ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

(MENAFN- EIN Presswire) Crohn's disease companies working in the market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma, and more. LAS VEGAS ...